CO5560580A2 - Formulaciones de sucralosa para disumular sabores desagradables - Google Patents

Formulaciones de sucralosa para disumular sabores desagradables

Info

Publication number
CO5560580A2
CO5560580A2 CO04015498A CO04015498A CO5560580A2 CO 5560580 A2 CO5560580 A2 CO 5560580A2 CO 04015498 A CO04015498 A CO 04015498A CO 04015498 A CO04015498 A CO 04015498A CO 5560580 A2 CO5560580 A2 CO 5560580A2
Authority
CO
Colombia
Prior art keywords
sucralose
active compound
liquid
disguise
taste
Prior art date
Application number
CO04015498A
Other languages
English (en)
Inventor
David Jaeger
Jay Dickerson
Annabelle Mogavero
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23195896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5560580(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5560580A2 publication Critical patent/CO5560580A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición farmacéutica que tiene un pH de desde aproximadamente 2.0 a aproximadamente 5.0 que comprendei) una base excipiente líquida que contiene en 100 mI aproximadamente 50 mg a aproximadamente 300 mg de sucralosa para disimular un sabor amargo de cualquier ingrediente activo; yii) al menos un compuesto farmacéuticamente activo seleccionado del grupo que consiste de antihistaminas, descongestionantes, antitusivos, expectorantes, antibióticos, antineoplásticos,medicamentos anti-inflamatorios no esteroidales (NSAIDs) y medicamentos analgésicos, dicho compuesto farmacéuticamente activo disolviéndose o suspendiéndose en la base excipiente líquida.16.- Un método para disimular el sabor de al menos un compuesto activo farmacéuticamente aceptable con sabor desagradable, tal método comprende mezclar tal compuesto farmacéuticamente activo con sabor desagradable en una base excipiente líquida que contiene en 100 ml de base líquida aproximadamente 50 mg a aproximadamente 300 mg de sucralosa para disimular un sabor amargo de cualquier ingrediente activo, en donde la composición tiene un pH desde aproximadamente 2.0 a aproximadamente 5.0.
CO04015498A 2001-07-31 2004-02-23 Formulaciones de sucralosa para disumular sabores desagradables CO5560580A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30891201P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
CO5560580A2 true CO5560580A2 (es) 2005-09-30

Family

ID=23195896

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04015498A CO5560580A2 (es) 2001-07-31 2004-02-23 Formulaciones de sucralosa para disumular sabores desagradables

Country Status (13)

Country Link
US (2) US20060121066A1 (es)
EP (1) EP1411955A4 (es)
JP (2) JP2004538309A (es)
AU (1) AU2002324579B2 (es)
BR (1) BR0211794A (es)
CA (1) CA2455939C (es)
CL (1) CL2004000208A1 (es)
CO (1) CO5560580A2 (es)
CR (1) CR7264A (es)
EC (1) ECSP044995A (es)
MX (1) MXPA04001026A (es)
NZ (1) NZ530889A (es)
WO (1) WO2003011306A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
JP2013053136A (ja) * 2011-08-09 2013-03-21 Taisho Pharmaceutical Co Ltd 内服液剤
WO2013084090A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
US20150056288A1 (en) 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3069733B1 (en) * 2013-11-13 2022-08-10 National Defense Education and Research Foundation New acetaminophen compound composition without side effect to liver
JP6565334B2 (ja) * 2014-06-18 2019-08-28 大正製薬株式会社 固形製剤
CN105640956B (zh) * 2014-11-14 2018-09-14 澳美制药厂有限公司 不含防腐剂的复方磷酸可待因组合口服液及其制备方法
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20160317497A1 (en) * 2015-05-01 2016-11-03 Trinity Ent And Facial Aesthetics Flavored analgesic and decongestant spray
JP6794758B2 (ja) * 2015-10-21 2020-12-02 大正製薬株式会社 経口液体医薬組成物
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4293009A3 (en) 2015-12-22 2024-02-21 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US20210069127A1 (en) * 2017-03-27 2021-03-11 DXM Pharmaceuticals, Inc. Multi-Dose Concentrated Liquid Diphenhydramine HCl Compositions and Packaged Multi-Dose Liquid Diphenhydramine HCl Formulations
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN112439072A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种掩味组合物及其制备方法、用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5374569A (en) * 1992-09-21 1994-12-20 Siliconix Incorporated Method for forming a BiCDMOS
EP0620001A1 (en) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
CZ210496A3 (en) * 1994-01-24 1996-12-11 Procter & Gamble Method improving solution process of difficult-to dissolve pharmaceutically active compounds
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
JP2000135055A (ja) * 1998-10-29 2000-05-16 Sanei Gen Ffi Inc 乳感の向上した乳含有製品
EP1216044A1 (en) * 1999-09-29 2002-06-26 The Procter & Gamble Company Compositions having improved stability
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen

Also Published As

Publication number Publication date
JP2010090142A (ja) 2010-04-22
BR0211794A (pt) 2004-11-03
US20110136851A1 (en) 2011-06-09
JP2004538309A (ja) 2004-12-24
US20060121066A1 (en) 2006-06-08
ECSP044995A (es) 2004-04-28
AU2002324579B2 (en) 2007-11-15
CA2455939C (en) 2011-03-22
EP1411955A4 (en) 2006-07-05
CL2004000208A1 (es) 2005-03-18
CR7264A (es) 2004-05-17
CA2455939A1 (en) 2003-02-13
EP1411955A1 (en) 2004-04-28
MXPA04001026A (es) 2005-06-20
WO2003011306A1 (en) 2003-02-13
NZ530889A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
WO2005065646A3 (en) Novel drug compositions and dosage forms
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
HUP0204110A2 (hu) Amfifil prodrugok, eljárás az ezeket tartalmazó gyógyszerkészítmények előállítására és alkalmazására
WO2004002447A3 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ATE261301T1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende arzneimittel
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2000048445A3 (de) Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
DE50010973D1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
BR0302523A (pt) Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
ES2295787T3 (es) Forma de dosificacion farmaceutica solida que comprende cafeina.
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени

Legal Events

Date Code Title Description
FC Application refused